Feasibility, Safety and QoL After Merendino Procedure

The Merendino Procedure for Benign or Early Malignant Lesions of the Distal Esophagus/Gastroesophageal Junction is Feasible, Safe and Provides Good QoL

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02855333

Acronym

MER

Enrollment

Registered

2016-08-04

Start date

2014-05-31

Completion date

2016-05-31

Last updated

2016-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign or Early Malignant Lesion of the Distal Esophagus or Gastro-esophageal Junction Requiring Surgical Resection

Keywords

Merendino procedure, Feasibility, Safety and QoL of the Merendino procedure

Brief summary

The purpose of this study is to analyse retrospectively the early postoperative and functional outcome of patients (pts) after Merendino procedure for benign or early malignant lesions of the distal part of the esophagus or the gastroesophageal junction.

Detailed description

Between 2004 and 2013, 14 pts had transhiatal resection of median 8 (6-10) cm of distal esophagus including the gastroesophageal junction. Locoregional lymphadenectomy was performed in all patients with (suspected) early adenocarcinoma. In case of vagus nerve resection, pyloromyectomy and cholecystectomy were done. A pediculated isoperistaltic jejunal segment of 15-18 cm length was interponed between esophageal stump and remaining stomach by end-to-side anastomoses. At least one postoperative contrast examination of the anastomoses was done in all pts. Quality of life was assessed by using the EORTC QLQ-OES18 survey, recording patients' general activity and condition and specific gastrointestinal symptoms.

Interventions

OTHEREORTC and QLQ-C30 / QLQ-OES24 questionnaire

EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* alive * MER or CON procedure * informed consent * CON patients were matched according to diagnosis, Age and ASA score

Exclusion criteria

* withdrawal of informed consent * legal incapacity * limitations in mental state or medical condition precluding questioning (only QoL data)

Design outcomes

Primary

Measure	Time frame	Description
Quality of Life (QoL)	up to 10 years after surgery	EORTC QLQ-C30 and QLQ-OES24 questionnaire (global health status item, functional and symptom scale items)

Secondary

Measure	Time frame	Description
Intraoperative complications	up to 1 day after surgery	Blood loss (ml), requirement for blood transfusion (units), operation time (min)
Postoperative complications	up to 100 days after surgery	Morbidity (re-intervention rate, re-operation rate), in-hospital mortality

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026